Watch: the CureRays® explainer series
Prefer to read? The full guide below is complete on its own, with tables you can revisit any time.
What is lacrimal gland carcinoma?
The lacrimal gland sits in the upper outer corner of the eye socket and makes the watery part of your tears. Cancers of this gland are rare, and the most common and most challenging is adenoid cystic carcinoma, a tumor that grows slowly but has a strong tendency to creep along the tiny nerves around the eye (perineural invasion), which makes it hard to remove completely and prone to coming back. Other lacrimal gland cancers include carcinoma arising in a previously benign mixed tumor and several less common types. Patients often notice a firm lump near the upper outer eyelid, a bulging or downward-and-inward displaced eye, double vision, or pain — pain being a clue that points toward cancer rather than a benign growth. Historically, treatment meant removing the entire eye and surrounding tissue, but modern care increasingly favors eye-preserving surgery combined with high-dose radiation. Because these tumors invade along nerves and sit beside the eye, brain, and optic nerve, specialized radiation — proton beams or neutron beams at expert centers — is used to deliver a strong, shaped dose while sparing vision. Some centers also use chemotherapy delivered into the artery feeding the gland before surgery. Long-term follow-up is essential because adenoid cystic carcinoma can recur or spread to the lungs many years later.
The main types
Doctors group lacrimal gland carcinoma by where it starts and how it behaves:
| Type | What it means, simply |
|---|---|
| Adenoid cystic carcinoma of the lacrimal gland | The most common and most aggressive type; grows slowly but invades along nerves, so treatment pairs surgery with high-dose proton or neutron radiation and long follow-up. |
| Carcinoma ex pleomorphic adenoma (in a benign mixed tumor) | A cancer that develops within a previously benign mixed tumor of the gland; the extent of invasion beyond the original tumor drives treatment and outlook. |
| Other lacrimal gland carcinomas | Less common types such as ductal or mucoepidermoid carcinoma; managed with surgery and radiation tailored to the type and how far the tumor extends. |
Staging, in plain terms
These cancers are staged by the size and extent of the tumor within the eye socket, whether it has eroded into nearby bone, and whether it has spread to lymph nodes or distant organs. For adenoid cystic carcinoma in particular, whether the tumor is invading along nerves is a critical feature because it predicts how widely treatment must reach. Most lacrimal gland cancers stay local for a long time but can recur or spread late, especially to the lungs.
| Lacrimal gland carcinoma TNM (AJCC) with grade and perineural invasion | What it generally means |
|---|---|
| Localized | Tumor confined to the gland and eye socket. Treated with eye-preserving surgery plus high-dose radiation (often proton or neutron) to control microscopic and perineural spread. |
| Locally advanced | Tumor invading nearby bone or extending more widely in the socket. May require more extensive surgery; radiation is central, and chemotherapy is sometimes added. |
| Metastatic | Spread to distant organs, most often the lungs, which can occur years later. Treated with systemic therapy and focused radiation for symptom control. |
The standard of care
Lacrimal Gland Carcinoma is almost always treated by a team that may include a surgeon, a medical oncologist, and a radiation oncologist, combining therapies for the best result. The usual building blocks are:
Eye-preserving surgery
Removing the tumor while sparing the eye whenever feasible is increasingly standard, replacing the older approach of removing the whole eye and socket contents in many patients.
High-dose adjuvant radiation (proton or neutron)
Radiation after surgery improves local control by treating cells that have crept along nerves; proton and neutron beams deliver a strong, shaped dose while protecting the eye, optic nerve, and brain.
Neoadjuvant intra-arterial chemotherapy (selected centers)
Some expert centers give chemotherapy directly into the artery supplying the gland before surgery, which has improved outcomes in adenoid cystic carcinoma in their experience.
Long-term surveillance
Because adenoid cystic carcinoma can recur or spread to the lungs many years later, regular eye examinations, imaging, and chest follow-up continue for a long time.
How radiation treatment works
Radiation damages the DNA inside cancer cells so they can no longer divide and survive, while healthy cells are better at repairing themselves. Lacrimal gland cancers — especially adenoid cystic carcinoma — invade along the small nerves around the eye, so radiation is shaped to cover not just the tumor but the nerve pathways it may have followed. Because the eye, optic nerve, and brain sit right next to the target, specialized particle beams (proton or neutron) are used at expert centers to deliver a high, tumor-killing dose while sparing those delicate structures and protecting vision. Radiation is given as short, painless daily sessions and leaves no radioactivity in your body, so you remain safe to be around family and children.
The main ways radiation is delivered for lacrimal gland carcinoma:
Surgery
Removes the tumor, ideally preserving the eye; the goal is to take out as much disease as possible while protecting vision and the structures of the socket.
Proton / neutron radiation
Particle beams concentrate a high dose on the tumor and the nerve pathways it may follow while sparing the eye, optic nerve, and brain just beyond the target.
Chemotherapy (selected)
Given into the feeding artery before surgery at some centers, or systemically for advanced disease, to shrink the tumor and treat spread.
Latest studies shaping care
Care keeps improving — often toward getting the same excellent results with less burden on patients. A few developments:
High-dose proton radiation improves outcomes: Series of lacrimal gland adenoid cystic carcinoma show that eye-preserving surgery combined with high-dose adjuvant proton radiotherapy achieves favorable local control with acceptable toxicity, supporting its use as an eye-sparing strategy.[1]
Lacrimal gland proton-therapy studies (2020–2025)
Toward eye preservation: Reviews report a shift away from routine removal of the eye toward globe-sparing surgery plus radiation, with novel adjuvant approaches — including intra-arterial chemotherapy and particle radiation — improving survival in this historically difficult cancer.[2]
Lacrimal gland carcinoma treatment reviews (2023–2025)
Long-term and late recurrence patterns: Outcome analyses confirm that adenoid cystic carcinoma of the lacrimal gland can recur locally or spread to the lungs years after treatment, with 5-year survival still under 60%, underscoring the need for prolonged follow-up.[3]
Lacrimal gland adenoid cystic carcinoma meta-analyses (2023–2025)
Common questions
Will I lose my eye? Not necessarily. Modern care increasingly favors eye-preserving surgery combined with high-dose radiation rather than removing the whole eye. Whether the eye can be saved depends on how far the tumor extends, and your team will aim to protect both your vision and your chance of cure.
Why is special proton or neutron radiation used? These cancers invade along nerves and sit right next to the eye, optic nerve, and brain. Proton and neutron beams can deliver a strong dose to the tumor and nerve pathways while sparing those delicate structures, improving local control while protecting vision.
Why do I need follow-up for so many years? Adenoid cystic carcinoma grows slowly and can come back at the original site or spread to the lungs many years later. Long-term eye exams, imaging, and chest checks let your team catch any recurrence early, when it is most treatable.
References
Numbered sources for the studies cited above. Links open the primary publication on PubMed or the publisher’s site.
- Lacrimal gland proton-therapy studies (2020–2025) (no indexed identifier — see your care team) ↩
- Lacrimal gland carcinoma treatment reviews (2023–2025) (no indexed identifier — see your care team) ↩
- Lacrimal gland adenoid cystic carcinoma meta-analyses (2023–2025) (no indexed identifier — see your care team) ↩